Vismodegib resistant mutations are not selected in multifocal relapses of locally advanced basal cell carcinoma after vismodegib discontinuation.

M Ighilahriz, M Benfodda, H Sharpe, N Soufir, S Mourah, N Dumaz, M Battistella, A Savina, F Bouquet, S Nikolaev, N Basset-Seguin

OAI: oai:www.repository.cam.ac.uk:1810/294698 • DOI: 10.17863/CAM.41803

Hedgehog pathway inhibitors (HPI) inactivating SMO 1, have become first line treatment for patients with locally advanced BCC (laBCC). HPI safety and efficacy have been shown in clinical trials2,3. Nevertheless, common adverse events lead to treatment discontinuation.

Anilides Carcinoma Basal Cell Drug Resistance Neoplasm Humans Mutation Neoplasm Recurrence Local Pyridines Skin Neoplasms